clinical trial · NCT05712694
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Soft Tissue SarcomaADI PEG20Placebo
brief summary
To compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
started
Nov 29, 2023
primary completion
Dec 30, 2027
completion
Dec 30, 2027
last updated
Apr 20, 2026
detailed description
This is a global, multicenter, randomized, double-blind, placebo-controlled, parallel-group phase 3 trial that will compare the efficacy and safety in subjects with advanced or metastatic LMS previously treated with an anthracycline.
official title
ADI-PEG 20 or Placebo Plus Gemcitabine and Docetaxel in Previously Treated Subjects With Leiomyosarcoma (ARGSARC): A Randomized, Double Blind, Multi-Center Phase 3 Trial
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol